References

  1. Goldfischer S, Moore CL, Johnson AB, Spiro AJ, Valsmis MP, Wisniewski HK, Ritch RH, Norton WT, Rain I, Gartner LM. Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome. Science 1973; 182: 62-64.
  2. Lazarow PB, Moser HW. Disorders of peroxisome biogenesis. In: The Metabolic Basis of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (editors). 7th CD-ROM edition, New York: McGraw-Hill, 1997: records 38247-38973.
  3. Bowen P, Lee CSN, Zellweger H, Lindenberg R. A familial syndrome of multiple congenital defects. Bull Johns Hopkins Hosp 1964; 114: 402-414.
  4. Powers JM, Moser HW. Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol1998; 8: 101-20.
  5. Martinez, M. Developmental Profiles of polyunsaturated fatty acids in the brain of normal infants and patients with peroxisomal diseases:Severe deficiency of docosahexaenoic acid in Zellwegers’ and pseudo-Zellwegers’ syndromes,EnA.P. Simopoulos (Ed.), World Review of Nutrition and Dietetics, S. Karger, Basilea 1991; 87-102.
  6. Martinez M. Altered unsaturated fatty acid patterns in Zellweger syndrome. Neurochem Int 1988; suppl 1: 148.
  7. Martinez, M. Changes in the polyunsaturated fatty acid profiles in Zellweger syndrome suggesting a new enzymatic defect: Æ-4 desaturase deficiency, en Dietary Omega-3 and Omega-6 Fatty Acids, editado por C. Galli y A.P. Simopoulos, Plenum Publishing Corporation, New York 1989; 369-372.
  8. Martinez, M. Polyunsaturated fatty acid changes suggesting a new enzymatic defect in Zellweger syndrome, Lipids 1989; 24: 261-265.
  9. Martinez, M. Severe deficiency of docosahexaenoic acid in peroxisomal disorders: A defect of Æ4-desaturation? Neurology 1990; 40: 1292-1298.
  10. Martinez, M.. Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders. Brain Res 1992; 583: 171-182.
  11. Martinez, M.., Severe changes in polyunsaturated fatty acids in the brain, liver, kidney, and retina in patients with peroxisomal disorders, In N. Bazan (Ed.), Neurobiology of Essential Fatty Acids, Plenum, New York, 1992; 347-359.
  12. Martinez, M. Tissue levels of polyunsaturated fatty acids during early human development, J. Pediat. 1992; 120: S129-138.
  13. Martinez M. Polyunsaturated Fatty Acids in the Developing human Brain: Influence of Nutrition and Peroxisomal Disease, en C. Galli (Ed) Fatty Acids and Lipids from Cell Biology to Human Disease. World Rev. Nutr. Diet. 1994; 75: 70-78.
  14. Martinez M, Mougan, I, Roig, M, and Ballabriga, A, Blood polyunsaturated fatty acids in patients with peroxisomal disorders. A multicenter study, Lipids 1994; 29: 273-280.
  15. Martinez M, Mougan I. Fatty acid composition of brain glycerophospholipids in peroxisomal disorders. Lipids 1999; 34: 733-40.
  16. Martinez, M., Docosahexaenoic acid: A new therapeutic approach to peroxisomal patients. ULF News 1992; 9: 2-4.
  17. Martinez, M.. Treatment with docosahexaenoic acid favorably modifies the fatty acid composition of erythrocytes in peroxisomal patients. In PM Coates and K Tanaka (Eds) New Developments in Fatty Acid Oxidation, Wiley-Liss, New York, 1992; 389-397.
  18. Martinez, M.., Pineda, M., Vidal, R., and Martin, B., Docosahexaenoic acid – A new therapeutical approach to peroxisomal-disorder patients: Experience with two cases, Neurology 1993; 43: 1389-1397.
  19. Martinez, M, Conde, C. and Ballabriga, A., Some chemical aspects of human brain development. II. Phosphoglyceride fatty acids, Pediat. Res. 1974; 8: 91-102.
  20. Martinez, M., and Ballabriga, A., A chemical study on the development of the human forebrain and cerebellum during the brain Ògrowth spurtÓ period. I. Gangliosides and plasmalogens, Brain Res., 1978; 159: 351-362.
  21. Ballabriga, A. and Martinez, M., A chemical study on the development of the human forebrain and cerebellum during the brain Ògrowth spurtÓ period. II. Phosphoglyceride fatty acids, Brain Res., 1978; 159: 363-370.
  22. Martinez M., Mougan I. Fatty acid composition of human brain phospholipids during normal development. J. Neurochem. 1998; 71: 2528-2533.
  23. Martinez, M. Myelin in the developing human cerebrum, Brain Res. 1986; 364: 220-232.
  24. Martinez, M. Myelin lipids in the developing cerebrum, cerebellum, and brain stem of normal and undernourished children, J. Neurochem. 1982; 39: 1684-1692.
  25. Martinez M. Biochemical changes during early myelination of the human brain, en Developmental Neurobiology, editado por P. Evrard y A. Minkovski, Raven Press, New York 1989;. 185-200.
  26. Martinez, M., and Ballabriga, A., Effects of parenteral nutrition with high doses of linoleate on the developing human liver and brain, Lipids 22: 133-138, 1987.
  27. Martinez, M., Gil-Gibernau, J.J., and Ballabriga, A. Lipids of the developing human retina: I. Total fatty acids, plasmalogens, and fatty acid composition of ethanolamine and choline phosphoglycerides. J. Neurosci. Res. 1988; 20: 484-490
  28. Martinez M. Polyunsaturated fatty acids in the developing human brain, erythrocytes and plasma in peroxisomal disease: therapeutic implications. J Inher Metab Dis 1995; 18 Suppl. 1, 61-75.
  29. Mart’nez, M. Docosahexaenoic acid therapy in DHA-deficient patients with disorders of peroxisomal biogenesis, Lipids 1996; 31: S145-152.
  30. Martinez M. Docosahexaenoic acid ethyl ester as a treatment for patients with generalized peroxisomal disorders. In Lipids in Infant Nutrition. Y.S.Huang, AJ Sinclair (editors). Champaign, Illinois: AOCS Press. 1998, pp. 29-38.
  31. Martinez, M., Vazquez. E. MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders. Neurology 1998; 51: 26-32.
  32. Martinez, M., Vazquez. E, Garc’a Silva, M.T., Manzanares, J., Bertran, J.M., Castell—, F., Pineda, M.y Mougan, I. Tratamiento de las enfermedades peroxisomales generalizadas con etil ester del ‡cido docosahexaenoico. Rev. Neurolog’a 1998; 28: S59-64.
  33. Martinez, M., Vazquez. E, Garc’a Silva, M.T., Manzanares,J., Bertran, J.M., Castell—, F., Pineda, M. y Mougan, I. Terapeutical effectsof docosahexaenoic acid in patients with generalized peroxisomal disorders. Am.J. Clin. Nutr. 2000; 71: 376S-385S .
  34. Martinez M, The fundamental and practice of docosahexaenoic acid therapy in peroxisomaldisorders. Curr Opin Clin Nutr Metab Care 2000; 3: 101-108.
  35. Martinez M, Restoring the DHA levels in the brains of Zellweger patients. Journal of Molecular Neurscience 2001; 16: 225-232.
  36. Martinez M, Enfermedadesperoxisomales generalizadas: nuevas posibilidades terapŽuticas. In: Tratamientode las enfermedades metab—licas. P. Sanjurjo and A. Baldellou (Ed.). EditorialErgon, 2001.